Retinal Vasculitis
Phase 2b trial of CLS-AX for wet AMD achieves primary, secondary outcomes
A phase 2b clinical trial of CLS-AX, a tyrosine kinase inhibitor under evaluation for the treatment of wet age-related macular degeneration, achieved its primary and secondary outcomes, according to a Clearside Biomedical press release.
Fluorescein angiography essential to identify retinal vasculitis
FORT LAUDERDALE, Fla. — Rare cases of occlusive retinal vasculitis have occurred with intravitreal therapies, and fluorescein angiography is an important tool to identify and diagnose the condition, according to a speaker here.
Phase 2 nonproliferative diabetic retinopathy trial misses primary endpoint
SEATTLE — The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.
Clinicians must weigh risks of geographic atrophy medications
WAILEA, Hawaii — Clinicians need to balance the efficacy of geographic atrophy medications with the risks, according to a speaker at Retina 2024.
Woman presents with ‘muddy’ spots in vision
A 39-year-old woman was referred to the New England Eye Center complaining of new-onset intermittent “muddy” spots in her vision. She had no associated vision loss, flashes, floaters or eye pain.
Apellis recommends Syfovre injection kits with 18-gauge filter needles
Apellis Pharmaceuticals has identified internal structural variations in the 19-gauge filter needle included in certain Syfovre injection kits as part of its investigation into the recent reports of retinal vasculitis.
Apellis: No drug product, manufacturing issues contributed to Syfovre inflammation reports
SEATTLE — Apellis Pharmaceuticals reported there is no indication that drug product or manufacturing issues contributed to recent reports of retinal vasculitis linked with Syfovre.
Most retinal vasculitis, vascular occlusion events after brolucizumab occurred in women
A systematic review of real-world evidence described 70 eyes of 63 patients with retinal vasculitis or vascular occlusion following treatment with brolucizumab for neovascular age-related macular degeneration.
BLOG: What’s next for Beovu?
On the heels of the major announcement from Novartis that Beovu should not be used in intervals less than 8 weeks, some are wondering what the ultimate future of the drug will be.
Retina specialists receptive but cautious regarding use of Beovu
While further analysis of trial data confirms efficacy and safety events in real-world practice continue to be monitored, the attitude of retina specialists toward the newest FDA-approved anti-VEGF agent remains open but cautious.